BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JNJ-87890387 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JNJ-87890387\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06178614-11227@assetmemo.bio
DTSTAMP:20261121T010440Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:JNJ-87890387: Phase 1 readout est. (NCT06178614)
DESCRIPTION:JNJ-87890387\, phase 1\, Advanced Solid Tumors.\nStudy: A Study
  of JNJ-87890387 for Advanced Solid Tumors\nEstimated primary completion: 
 16 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jnj-87
 890387#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06178614
URL:https://assetmemo.bio/drug/jnj-87890387#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
